Safety and Immunogenicity of Personalized Genomic Vaccine to Treat Malignancies

NCT02721043 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

13

Enrollment

OTHER

Sponsor class

Conditions

Solid Tumors

Interventions

BIOLOGICAL: Peptides
DRUG: Poly-ICLC
DRUG: Lenalidomide

Sponsor

Nina Bhardwaj